We may be in the cliffs of an important moment in researching Alzheimer's disease. In the clinical experiments published this week, scientists have presented the preliminary evidence that it is possible to slow down the symptoms in people with genetic fate to develop Alzheimer at a young age.
The researchers at the Faculty of Medicine, Washington University are the leaders of education, which aim to test whether anti -Amloid drugs are called Ganannerumab. Can people with the inherited Alzheimer's symptoms? In the longest group of patients, drugs seem to reduce the risk of developing symptoms as expected. 50%. This discovery must be followed up. But the outer experts are carefully optimistic about this may mean the future of Alzheimer's treatment.
“The results are clear that there is a good hope that the pathological treatment (Alzheimer's) in the pre -clinic period of the pathology may be effective in slowing down or preventing diseases caused by the disease. Not involved in research. Tell GizModo.
Gantenderumab Is one of the many similar drugs that scientists develop for Alzheimer's It is an antibodies made from the laboratory targeting the beta Amloid, one of the two proteins that will play an important role in the cause of Alzheimer's (other as unity) in people with Amyloid's wrong Alzhelid disease. Scientists have the theory that it is possible to stop, or at least slowing down the Alzheimer's with drugs such as Ganannerumab that decay and prevent these pipes from occurring.
Unfortunately, it is not a smooth matter for this hypothesis. Many Amyloid drugs have demonstrated the promise. But only will fail in a large experiment that tested them for those who started to experience the symptoms of Alzheimer's symptoms. That item includes Gannerumab; At the end of the year 2022, Yoros Company Close development Of the drug after the 3rd trial failure
But Amyloid recently demonstrated a simple result. But clearly in the slowdown of Alzheimer's, enough to be approved by the Food and Drug Administration Some researchers, including Washu Medicine, hope that the anti -amyloid treatment may be more effective when the drug is long before the appearance of Alzheimer's symptoms.
Beginning in 2012, researchers and others launched the experiment to prevent anti -Amloid representatives in people with outstanding Alzheimer's symptoms, which are all genetic conditions. But guarantees the development of dementia during the age of 30 and 50 of the individual. Most of these experiments are not successful, except that it is possible for those who have Gantendineab.
When the original Ganannerumab study summarized in 2020, researchers found that it was reduced by people. But it is too early to know whether it may slow down the symptoms of people or not, because most patients at the beginning of the study did not expect to be sick for 10 to 15 years. (Including those who take pills or other drugs) as part of the study of extensions
It was the latest result of this study published on Wednesday at Lancet Neurology that was excited.
“Everyone in this study is determined to develop Alzheimer's disease and some people have not yet.” Randall J. Bateman, the senior author of the neurology of Washu Medicine, said in A. statement From university “We still do not know what they will still have symptoms without symptoms for a few years or decades.”
That says that there is a condition that is important for education
For one, the discovery of a hint that receives protective benefits that may occur. Wisniewski says those drugs may reduce the risk of knowledge, understanding, and understanding among people without this. (May be due to the low number of patients in a total of 73 studies. Overall, Wisniewski said) in the sub -patients with the longest – about eight years of treatment. – The average drug seems to reduce the chances of the expected to be reduced by 50% of the knowledge, but this 22 sub -patients include a smaller sample size.
The experiment ends faster than expected for many patients due to the abandonment of Roch's drugs and some people go out for other reasons. Drugs seem to be safe and resistant, although there are about one -third of Arias Arias Arias or the Arias Arias's swelling or bleeding, although most of these drugs are noticed by patients. Two patients succeeded in Arias, which encourages researchers to stop treatment. After that, they recover. There is no report of events or death that threatens life during education.
Overall, education is not a clear proof that anti -Amloid drugs can work for Alzheimer's advance. But since this form is inevitable, these results are the first time from clinical experiments to suggest that it can be treated. When combined with the previous approval of LeCanemab and Donanemab for classic nervous system disorders, there seems to be nothing true here.
“We already know from the Lecaneemab and Donanemab data that anti -AAAS antibodies (AAAS) can slow down the progress of Alzheimer's disease periodically.” Sam Grade, the director of the Alzheimer's Disease Research Center, Mount Sina, said to the GizModo, “The article focuses on using different AAA uses. (Gantendrumab) to show similar phenomena that is true in genetic in the early Alzheimer's range. “
Grady, Wisniewski and educational researchers agree that this is only the beginning. There is a continuous preventive experiment at the moment, both in the beginning and Alzheimer's classicInclude many Operated by Washu through the outstanding Alzheimer's network experiment. These experiments are approved tests and anti -Amloid drugs. Noewer that can show more protection benefits than Ganannerumab. Researchers can also change a lot of patients in existing extensions to lecanemab, although the data from this phase is still analyzed.
It's the first day But there may be truly hope for the disease that cannot be healed on the horizon.